Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
Noosa News22 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News22 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
Noosa News24 hours agoHelicopter scrambles to site of air crash on K’gari
-
General21 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off